CHM have a 10 -30% chance of trophoblastic sequelae. CHM includes androgenic homozygous (monospermic) and androgenic heterozygous (dispermic) moles. It is controversial whether the risk of GTN is higher with heterozygous than with homozygous CHM. A prospective cohort study was conducted to assess risk of GTN in homozygous and heterozygous CHM using short tandem repeat (STR) polymorphisms, and a meta-analysis of previous reports.
Introduction
Hydatidiform mole (HM) is an abnormal pregnancy with nonneoplastic proliferation of trophoblasts and a hydropic swelling of the chorionic villi, with or without a fetus (Wells, 2007) . It occurs in about 1 in 1000 pregnancies in Western countries and is somewhat more frequent in Asian countries (Hayashi et al., 1982) .
The diagnosis of HM is of clinical importance because HM is a highrisk antecedent pregnancy for gestational trophoblastic neoplasia (GTN), including invasive mole and choriocarcinoma (Berkowitz and Goldstein, 2009) . There are two different HM entities: androgenic diploid 'complete' hydatidiform mole (CHM) and triploid 'partial' hydatidiform mole (PHM). CHM has a higher risk of GTN than PHM. It has been estimated that 10-30% of CHM develops GTN (Benedet et al., 2000) , whereas 0.5% of PHM develops GTN (Seckl et al., 2000) . It has not yet been determined whether PHM is truly a risk factor for GTN, albeit a lower risk than CHM (Niemann et al., 2006) . Accurate distinction of CHM and PHM is, nevertheless, valuable to assess the risk of HM. This distinction has been made primarily based on microscopic findings, sometimes with the aid of traditional cytogenetic analyses (Benedet et al., 2000) .
With respect to the assessment of persistent gestational trophoblastic disease (GTD) risk, an intriguing hypothesis relevant to the cytogenesis of CHM distinction was proposed in 1984 (Wake et al., 1984) . CHM, androgenic diploid, consists of homozygous 'monospermic' CHM and heterozygous 'dispermic' CHM. Homozygous CHM is theoretically derived from an 'empty egg', an abnormal oocyte with no or an inactivated nucleus, fertilized with one sperm, which is followed by duplication of the haploid genome, whereas heterozygous CHM is derived from an 'empty egg' fertilized with two different sperms (Devriendt, 2005) . The working hypothesis proposed was that the risk of persistent GTD is higher for heterozygous CHM than for homozygous CHM (Wake et al., 1984) . Several researchers and groups have been working on this with different approaches. Wake et al. analyzed polymorphism of chromosome Q-band, HLA and phosphoglucuromutase I, and they found a marginal but statistically significant difference between heterozygous and homozygous CHM (Wake et al., 1987) . However, Lawler and Fisher, who analyzed Q-band polymorphism and biochemical polymorphisms of four enzymes (phosphoglucuromutase I, acid phosphatase-I, glyoxylase and esterase) found no significant difference between the two (Lawler and Fisher, 1987) . These traditional analyses using cytochemical and biochemical polymorphisms are not so powerful or accurate for the detection of heterozygosity, and actually more than one-third of cases were left undetermined in the two studies. Molecular genetic techniques, which improve the diagnostic power of heterozygosity, were introduced for CHM diagnosis in 1991 (Ko et al., 1991; Cho and Kim, 1993) . Three groups analyzed different sample sizes, using different methods; restriction fragment length polymorphisms of four loci (Cho and Kim, 1993) , chromosome in situ hybridization for the Y chromosome (Cheung et al., 1994) and short tandem repeat (STR) polymorphism for 10 loci on four chromosomes (Niemann et al., 2007) . They found no difference in the incidence of persistent GTD between homozygous CHM and heterozygous CHM. Since not many loci were analyzed, some heterozygous CHM could be misjudged to be homozygous CHM, which may confuse the result.
In reviewing these previous data, we noticed that occurrences of persistent GTD were consistently higher in heterozygous CHM than in homozygous CHM, although the difference failed to reach significant levels in all but one experiment. Thus, we conducted a prospective cohort study to determine the risk of heterozygous CHM, using the most recent, accurate and powerful system of human identity testing, and found that the risk for persistent GTD was higher in heterozygous CHM than in homozygous CHM in a Japanese sample.
Materials and Methods

Subjects
Twenty-eight consecutive cases of HM evacuated by dilation and curettage (D&C) at Chiba University Hospital between June 2007 and May 2009 were studied. Primary hysterectomy cases were excluded from this study. All patients were clinically diagnosed as having CHM at regional clinics and referred to our hospital before evacuation. All pathological diagnoses were made histologically after examination of hematoxylin and eosin-stained sections at the Department of Pathology in Chiba University Hospital. All patients and their partners were of Japanese origin. This study was approved by the Institutional Review Board of Chiba University Graduate School of Medicine (no. 165) and was performed after obtaining written informed consent from the patients and their partners. All patients and their partners gave their consent for this study, and all except four partners agreed to give their blood to be analyzed. Of 28 partners, 24 joined this study.
Clinical follow-up
After evacuation of the molar pregnancy, the patients were followed by weekly serum hCG assays (DPC Immulyze 2000; Siemens Healthcare Diagnostics, Tokyo, Japan) until their hCG levels returned to 50 mIU/ml, then biweekly to 5 mIU/ml and finally then monthly to normal (,1.0 mIU/ml). After serum hCG levels normalized, the patients visited our hospital 3 months later, and then every 6 months for 5 years. The median follow-up was 14.6 months (range 4.1 -27.3 months). GTN was diagnosed according to the International Federation of Gynecology and Obstetrics (FIGO) criteria for GTN and the FIGO scoring system (Kohorn, 2001 ) and treated by a single agent (methotrexate). Spontaneous remission was defined as normalization of the hCG level.
DNA preparation
The molar villous tissues were extensively washed with normal saline and then isolated from maternal decidua under a stereoscopic microscope. DNA extractions from villi and blood samples of patients and their respective partners were performed with a QIAamp w DNA Mini kit and QIAamp w Blood DNA Mini kit (QIAGEN K. K., Tokyo, Japan), respectively, according to the manufacturer's instructions. The concentration of genomic DNA preparation was determined by the absorbance at 260 nm with NanoDrop 1000 (Thermo Fisher Scientific, Inc., Waltham, MA, USA).
Multiplex PCR and genotyping
The PowerPlexw 16 System (Promega US, Madison, WI, USA) was used for genotyping. The system is a multiplex, three-color, fluorescence PCR system and amplifies 15 STR loci (the 13 loci of the Combined DNA Index System and two pentanucleotide loci referred to as Penta D and Penta E) and the amelogenin locus that occurs on both the X and Y chromosomes and enables sex typing (Krenke et al., 2002; Butler, 2006) . Amplification was performed according to the manufacturer's instructions using 1 ng of genomic DNA. PCR products were analyzed with the ABI prism 310 Genetic Analyzer (Applied Biosystems, Inc., Foster City, CA, USA). Data analysis was performed using GeneScan software 3.1 (Applied Biosystems, Inc.).
Diagnostic algorithm for genetic classification
The subtypes of molar pregnancy were determined according to the algorithm shown in Fig. 1 . If at least one locus in molar DNA had three different alleles, it was classified as triploidy; otherwise, it was classified as diploidy.
The relationship between molar and maternal alleles was checked in each locus. If villous loci contained at least one maternal allele, the villi were considered biparental; otherwise, they were considered androgenic. If androgenic CHM had at least one locus with two different alleles of paternal origin, it was considered heterozygous CHM. Androgenic CHM that had only one allele of paternal origin in all loci was classified as homozygous. No mutant alleles of different sizes from any maternal and paternal alleles were identified.
Statistical analysis
Student's t-tests were used to compare the clinical characteristics between the two groups. Fisher's exact tests were used to determine significant differences in the rate of GTN between homozygous and heterozygous moles. The statistical analyses were performed using JMP8.0 (SAS Institute, Cary, NC, USA). Meta-analysis of the retrieved data from the literature was performed using Review Manager (RevMan) v.5.0.21 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark) with Mantel-Haenszel methods under a fixed-effects model. A P , 0.05 was considered significant.
Results
Patient characteristics, genotyping and clinical outcome
The patients' clinical characteristics are shown in Table I . Their mean age was 34.3 + 7.6 years (median, 33.9 years; range 22.4-52.0 years), and the mean gestational age at D&C was 10.6 + 2.5 weeks (median, 10.3 weeks; range 5.7 -17.1 weeks).
Genotyping
Genotype was successfully determined in all pairs of molar tissues and patient blood. Paternal origin of the molar tissue was also confirmed by analysis of the paternal blood except in four cases in which paternal samples were not available. Two examples of electropherograms are shown in Fig. 2 : an example of androgenic homozygous mole of monospermic origin ( Fig. 2A ) and an example of heterozygous CHM of dispermic origin (Fig. 2B ).
There were 24 cases of androgenic homozygous CHM (cases 2 -25), three cases of androgenic heterozygous CHM (cases 26 -28) and one case of triploidy PHM (case 1). In all three cases of heterozygous CHM, paternal origin was confirmed by the analysis of paternal genotypes.
Gestational trophoblastic neoplasia
Of the 28 patients, nine eventually progressed to low-risk GTN according to the FIGO scoring system and received chemotherapy. The incidence of GTN was 6 of 24 (25%) for homozygous CHM, three of three (100%) for heterozygous CHM and zero of one (0%) for PHM. Using Fisher's exact probability test, there was a significant difference in the rate of development of persistent disease between homozygous and heterozygous CHM (P ¼ 0.029).
To clarify the clinical characteristics of heterozygous CHM, its clinical parameters were compared with those of homozygous CHM (Table II) . The mean values of maternal age, gravidity, parity and b-hCG before D&C and gestational age at D&C were not significantly different between homozygous and heterozygous CHM, although the maternal age of heterozygous CHM tended to be older.
To extract clinical parameters that might predict GTN occurrence, clinical parameters were compared between cases developing GTN and those not developing GTN (spontaneous remission) (Table III) . Although not significant, earlier evacuation appeared to be marginally associated with GTN development.
Meta-analysis
A systematic and cross-referenced search of relevant publications revealed that there were only a few publications reporting persistent GTD occurrence of every zygosity of CHM. The sample size was also small in all publications, and only five reports that were selected included more than 15 CHMs in total. The methods for zygosity analysis, the sample size and the race of the subjects were, however, different. When the data were pooled using Mantel-Haenszel methods under a fixed-effects model across these five studies, the odds ratio of heterozygous CHM to homozygous CHM was 2.00; the difference just failed to reach the significant level (95% confidence interval: 0.98-4.07) (Fig. 3) .
Discussion
The present cohort study demonstrated that heterozygous CHM had a higher potential for GTN than homozygous CHM. A total of 28 consecutive cases of pre-evacuated CHM was enrolled and prospectively managed. The difference in GTN risk between heterozygous and homozygous CHM was significant, although the sample size was small.
In this study, a human identity testing system involving multiplex PCR (PowerPlex w 16) and capillary electrophoresis with an automated DNA sequencer was used to determine zygosity. This method had several advantages over other methods used in previous studies (Butler, 2006) . First, this method was very powerful for distinguishing heterozygotes from homozygotes. Using STR polymorphism, heterozygosity is distinguished from homozygosity by the detection of a locus presenting two different alleles of paternal origin (as shown in the lowest two panels in Fig. 1) . Thus, the more heterologous loci (meaning loci with different alleles) used, the higher the power for the detection of heterozygosity. The PowerPlex w 16 system uses as many as 16 loci, all of which are highly variable in Japanese people as well as in Caucasians (Tie et al., 2006) . Moreover, these loci are distributed on 14 chromosomes (D5S818 and CSF1PO are on chromosome 5, and D21S11 and Penta D are on chromosome 21) and the 14 , Heterozygous CHM shows exclusively paternal alleles of dispermic origin. All molar loci consist of one or two peaks. Seven informative loci (D18S51, Penta E, D5S818, D7S820, Penta D, D8S1179 and FGA) indicate that the mole is of androgenic origin, and four loci, depicted by asterisks (D21S11, D13S317, D16S539 and Amelogenin), of heterologous alleles reveal that this is androgenic heterozygous CHM.
Complete hydatidiform moles and trophoblastic sequelae variables are therefore completely independent. Consequently, the diagnostic power of this system is quite high, and the probability that a 'true' heterozygote is misjudged as a homozygote is less than (1/2) n , where n is the number of heterologous and independent loci in the paternal genome, namely, the number of heterologous chromosomes. In this study, the actual number of heterologous loci of the paternal genome was in the range of 10 -16, and that of heterologous and independent loci, namely, heterologous chromosomes, was 8-14 (Table I ). The probability of failure to detect a heterozygote was therefore less than (1/2) 8 ¼ 0.0039.
Secondly, the method used in this study is highly accurate in discerning different alleles. DNA fragments amplified by PCR were Figure 2 Continued fractionated by capillary electrophoresis using an automated DNA sequencer, which consistently detects a 1 bp difference in 600 bp fragments. The PCR fragments in this method are 100 -450 bp long, and the difference between the alleles in each locus is a multiple of 4 or 5 bp, depending on the STR repeat number, which can be detected reliably by the DNA sequencer. Traditional polyacrylamide gel electrophoresis is, however, not very reproducible, making it difficult to discern the number of repeats when the difference in size or mobility is minimal. This is true especially in the analysis of biochemical polymorphism, but also even in DNA fragment analysis. Complete hydatidiform moles and trophoblastic sequelae
We re-analyzed the same STR loci of the DNA samples that had been previously analyzed and found that 'heterologous' alleles that had appeared in the traditional polyacrylamide gel electrophoresis were 'truly' homologous alleles on DNA sequencer analysis (these results are not included in this study). We initially thought that improvement of resolving power would identify more heterozygotes from homozygotes and that the number of heterozygotes would therefore increase. The reality was, however, unexpectedly reversed: the higher the resolution became, the more the single peak alleles were identified. Additionally, we conducted collateral analysis of both paternal and maternal samples in most cases to confirm allele origin, which further strengthened the fidelity of our result. As described earlier, there are conflicting reports on the GTN risk of heterozygous CHM. The occurrence of persistent GTD has been consistently reported to be higher in heterozygous CHM than in homozygous CHM, and the difference reached significant levels in two of six reports, including five previous publications and our results (Table IV) . Meta-analysis of previous publications also showed a marginal, though not significant, difference. There are several explanations for the inconsistency between studies. One possible explanation is that the sample sizes were too small to detect the difference. Suppose the risk ratio of heterozygous CHM is two or less, and the overall occurrence rate of GTN is around 20%, as suggested by the meta-analysis. Then, the sample size necessary to detect the difference is calculated to be about 600. The sample size was smaller than this in all previous studies, including the present study. Another explanation is ethnicity. The odds ratios were higher (5.03 in Wake's study and high in the present study, though impossible to calculate because of 100% occurrence), and the differences were significant in two Japanese studies, while the odds ratios were lower (1.54, 2.40, 1.61 and 1.45) and the differences were insignificant in four other studies. It is well known that there is a higher incidence of molar pregnancy in the Japanese population (Hayashi et al., 1982; Takeuchi, 1987) , and this may be related to the higher risk of GTN from heterozygous CHM.
If the risk of persistent GTN is higher with heterozygous CHM than with homozygous CHM, how does heterozygosity contribute to preferential persistence of trophoblast? One interesting theory proposed by Wake et al. is that the homozygous CHM is at a proliferative disadvantage because of homozygosity for recessive mutation(s) at certain loci necessary for autonomous cell proliferation (Wake et al., 1984) . Thus, trophoblast homozygous for the mutant allele (designated as P1) would disappear before forming persistent GTN, whereas others [carrying at least one wild-type allele (designated as P2)] would survive and give rise to persistent GTN with a constant probability (designated as k). Simply, given that this recessive locus is single, duplication of the single sperm genome as a mechanism of homozygous CHM would give rise to only two types of CHM: P1P1 and P2P2 at a probability of p and (12p), respectively, where p is the probability of the mutant allele, P1. Accordingly, the probability of GTN occurrence after homozygous CHM is given by k(12p). For the dispermic mechanism of heterozygous CHM, three types of CHM would be formed: P1P1, P1P2 and P2P2. P1P1 disappears without autonomous cell proliferation, and this occurrence is given by p 2 . Persistent GTN occurs from surviving CHM [P1P2 and P2P2, the probability of the summation of these two is given by (12p
2 )] at a rate of k. Consequently, the occurrence of GTN after heterozygous CHM is given by k(12p 2 ). Finally, the risk ratio of the occurrence of GTN is calculated as k(12p 2 )/k(12p), namely (1 þ p). The risk ratio was calculated to be 1.8 based on data retrieved from the previous reports and our study. If a risk ratio of 1.8 is adopted, p is calculated to be 0.8, and the incidences of GTN from homozygous and heterozygous CHM are (120.8) and (120.8 2 ), 0.2 and 0.36, respectively. These calculated incidences coincide well with the observed incidence of GTN shown in Table IV . If the 'true' risk ratio is under 2, the data from all studies reported are consistent with this theory. However, if we accept the relative risk as being .2 (Wake's and our study), we cannot explain it using this theory. Another possible explanation for the positive association between heterozygous CHM and developing GTN is confounding by maternal age. The mean maternal age of heterozygous CHM was 7.5 years older than that of homozygous CHM in this study, although the difference was not statistically significant. If there were a real difference, it might be possible to postulate that eggs from older women are more susceptible to overfertilization and, thus, developing heterozygous CHM. It is well known that older age is a risk factor of developing GTN (Benedet et al., 2000) . Collectively, the association of heterozygous CHM and developing GTN could be an apparent linkage confounded by maternal age. Further study with a greater number of patients is needed to determine whether heterozygous CHM increases with increasing maternal age.
In summary, using STR polymorphisms for classification, it was shown that heterozygous CHM had a greater risk of GTN than homozygous CHM. Heterozygous CHM diagnosed by 16-loci STR polymorphism analysis would be considered as a high risk CHM for GTN, although further cases are needed to accurately compare the risk of persistent disease for homozygous and heterozygous CHM. 
